Device Trial Radar · NCT07291739
A Clinical Evaluation of a Phakic Intraocular Lens
Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Aug 22, 2022
Primary completion
Oct 18, 2024
Study completion Oct 18, 2024
Sponsor
- Lead sponsor
- Staar Surgical CompanyNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 18, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the clinical performance of the STAAR EVO+ Visian™ Implantable Collamer® Lens with Aspheric (EDOF) Optic as refractive elements to correct or reduce myopia or hyperopia with presbyopia with or without astigmatism.
Conditions
- Myopia
- Hyperopia
- Astigmatism
- Presbyopia
Interventions
Implantable Collamer Lens (ICL)Device
EVO+ Visian Implantable Collamer Lens with Aspheric (EDOF) Optic models VTICM6/VTICH6 (TEDOF ICL) and VICM6/VICH6 (EDOF ICL)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in visual acuityTime frame: 1 month, 3 months and 6 months postoperatively
- Change in refractive cylinderTime frame: 1 month, 3 months and 6 months postoperatively
- Lens axis misalignmentTime frame: 1 month, 3 months and 6 months postoperatively
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asian Eye Institute
Makati City, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.